Selvigaltin

Selvigaltin (GB1211) is the first small-molecule, orally delivered galectin-3 inhibitor to be discovered.^[1] It is developed by Galecto Biotech, which is testing the molecule to see if it reduces decompensated cirrhosis^[2] and resistance to checkpoint inhibitors (a type of anti-cancer drug).^[3][4]

Other namesGB1211

Legal status

• Investigational

PubChem CID

• 122443488

IUPHAR/BPS

• 11202

Quick facts Clinical data, Other names ...

Selvigaltin

Clinical data
Other names	GB1211
Legal status
Legal status	Investigational
Identifiers
IUPAC name (2R,3R,4S,5R,6R)-2-(5-Bromopyridin-3-yl)sulfanyl-6-(hydroxymethyl)-4-[4-(3,4,5-trifluorophenyl)triazol-1-yl]oxane-3,5-diol
PubChem CID	122443488
IUPHAR/BPS	11202
ChemSpider	115010772
UNII	94EN2E6BLW
KEGG	D12763
ChEMBL	ChEMBL5182222
Chemical and physical data
Formula	C19H16BrF3N4O4S
Molar mass	533.32 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=C(C=C(C(=C1F)F)F)C2=CN(N=N2)[C@H]3[C@H]([C@H](O[C@@H]([C@@H]3O)SC4=CC(=CN=C4)Br)CO)O
InChI InChI=1S/C19H16BrF3N4O4S/c20-9-3-10(5-24-4-9)32-19-18(30)16(17(29)14(7-28)31-19)27-6-13(25-26-27)8-1-11(21)15(23)12(22)2-8/h1-6,14,16-19,28-30H,7H2/t14-,16+,17+,18-,19-/m1/s1 Key:FNCLKJPMEFPXOR-QFACEVIFSA-N

Close